Invitation to Presentation of BioInvent's Interim Report January - September 2022 on October 27, 2022

October 24, 2022 5:20 AM

LUND, SWEDEN / ACCESSWIRE / October 24, 2022 / BioInvent International (STO:BINV) - BioInvent International AB (Nasdaq Stockholm: BINV) invites to a presentation of the Q3 interim report and a telephone conference with CEO Martin Welschof and CFO Stefan Ericsson. The presentation will be held in English.When: 2:00 p.m. CEST, Thursday October 27, 2022.Listen to the presentation: https://ir.financialhearings.com/bioinvent-q3-2022To participate in...

Read more

Media Alert: BrainChip Exhibits its Essential AI Capabilities at the Linley Fall Processor Conference 2022

October 23, 2022 5:30 PM

LAGUNA HILLS, CA / ACCESSWIRE / October 23, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, today announced that Chief Development Officer Anil Mankar will present "System-Level Advances in Neuromorphic Performance, Efficiency, Configurability and Scalability" at the Linley Fall Processor Conference 2022 in the Hyatt Regency Hotel in Santa Clara,...

Read more

Petros Pharmaceuticals to Participate in Two October 2022 Conferences

October 21, 2022 8:00 AM

NEW YORK, NY / ACCESSWIRE / October 21, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will participate in two October 2022 conferences.LD Micro Main Event XV (Los Angeles, CA)Presentation Date: Tuesday, October 25Time: 4:30 pm PT (Track 4)The conference is being held on October 25 - 27, 2022 at the Luxe Sunset...

Read more

NovAccess Global Announces Fireside Chat with Board Member Perspectives

October 20, 2022 9:17 AM

Topic: Opportunities for the Biomedical Field and for ShareholdersCLEVELAND, OH / ACCESSWIRE / October 20, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its initial installment in a series of interviews with its corporate leadership on a monthly basis for the next four months, with additional sessions to be made available as company...

Read more

Biovica Appoints Anders Morén as CFO

October 20, 2022 2:15 AM

UPPSALA, SWEDEN / ACCESSWIRE / October 20, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, today announces that Anders Morén has been appointed as the company's Chief Financial Officer (CFO). Anders Morén will begin his new position on January 1, 2023.Most recently, Anders Morén comes from the global pharmaceutical company Gilead where he was responsible for the...

Read more

Biovica Submits CLIA Lab Application for DiviTum(R)TKa Launch

October 19, 2022 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / October 19, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica today announces that the company has submitted its CLIA lab application, marking yet another significant milestone for the US commercial launch of the recent FDA cleared test DiviTum®TKa. Biovica is now prepared to receive, analyze, and report results for its novel DiviTum®TKa diagnostic with capacity and capability to...

Read more

Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

October 18, 2022 8:00 AM

AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a...

Read more

Notice of Extra General Meeting in Biovica International AB

October 18, 2022 3:05 AM

UPPSALA, SE / ACCESSWIRE / October 18, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Monday 7 November 2022, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises at Vasagatan 7 in Stockholm.Right to attend the general meetingShareholders who wish to attend the general...

Read more

Midatech Pharma PLC Announces Receipt of NASDAQ Notification

October 18, 2022 2:00 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / October 18, 2022 / Midatech Pharma (AIM:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that further to the Company's announcement on 14 April 2022, it has received written notification dated 10 October 2022 (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ") that for 10 consecutive business days, from 26...

Read more

European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies

October 14, 2022 7:55 PM

VANCOUVER, BC / ACCESSWIRE / October 14, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One"), further to its press release dated August 18, 2022, is excited to announce its wholly owned subsidiary, Akome Biotech Ltd. ("Akome"), the Company's bio-pharma research and development division focused on new psychedelic-based drug discovery and development targeting neurological and mental health...

Read more

ITOCO Gives Shareholders Stronger Say in Company’s Future

October 14, 2022 2:50 PM

TORONTO, ON / ACCESSWIRE / October 14, 2022 / ITOCO INC. (OTC:ITMC) is pleased to announce that it is cancelling the existing voting block of shares that allowed control of the company to be held by one individual, thereby giving all shareholders a stronger voice in the future of the company."This is something that was long overdue and provides our shareholders with the opportunity to have more input into the company's growth," says CEO and...

Read more

Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners

October 14, 2022 2:00 AM

The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs)Its proprietary ADC technology opens the door for new and better treatment options for cancer patientsLYON, FRANCE / ACCESSWIRE / October 14, 2022 / Mablink Bioscience ("Mablink"), a biotechnology company aiming to transform cancer therapy using next-generation antibody-drug conjugates...

Read more

BrainChip Fortifies Neuromorphic Patent Portfolio with New Awards and IP Acquisition

October 12, 2022 7:25 PM

LAGUNA HILLS, CA / ACCESSWIRE / October 12, 2022 / BrainChip Holdings Ltd (ASX BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, has extended the breadth and depth of its neuromorphic IP with two new patents granted by the US Patents and Trademarks Office (USPTO), and the acquisition of previously licensed technology from Toulouse Tech Transfer (TTT). These latest additions of technical...

Read more

Chameleon Biosciences Presents Poster on AAV Gene Therapy Redosing Success at ESGCT

October 11, 2022 3:05 PM

The European Society of Gene & Cell Therapy (ESGCT) Welcomes Chameleon's Animal Study Results Poster at its 29th Annual Conference in Edinburgh, U.K.BERKELEY, CA / ACCESSWIRE / October 11, 2022 / - Chameleon Biosciences Inc., a biotechnology company focused on an innovative approach to produce safer, more effective gene therapies, will present "Use of EVADER AAV8 for repeat dosing in mice and non-human primates" in poster form at ESGCT's...

Read more

Organicell Regenerative Medicine, Inc. Announces Additions to Board of Directors

October 11, 2022 10:15 AM

Expanded Board of Director Broadens Company's Access to Valued Business Expertise and RelationshipsMIAMI, FL / ACCESSWIRE / October 11, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced that the Company has added independent board members to its board of directors.Dr. Bhupendra Kumar Modi (Dr....

Read more

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

October 11, 2022 8:05 AM

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancerFRAMINGHAM, MA / ACCESSWIRE / October 11, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced...

Read more

Viewpoint Molecular Targeting Announces Two New Grant Awards of $2 Million Each

October 11, 2022 8:00 AM

SBIR Phase II Grants bring the cumulative grant total to approximately $17 million from the National Institutes of Health and National Cancer InstituteCORALVILLE, IA / ACCESSWIRE / October 11, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the award of...

Read more

Eyam Announces Partnership with Mitacs to Fund Next Generation COVID-19 Vaccine Technologies

October 11, 2022 7:30 AM

VANCOUVER, BC / ACCESSWIRE / October 11, 2022 / Eyam Vaccines and Immunotherapeutics ltd. ("Eyam" or the "Company"), today announced a partnership with Mitacs to fund Post-Doctoral Fellowships at the University of British Columbia (UBC).Mitacs, is a not-for-profit organization that fosters growth and innovation, and will provide equal funding for research efforts at UBC that will directly support Eyam's leading vaccine development programs for...

Read more

Vaso Corporation Announces Up-listing to OTCQB Market

October 6, 2022 9:00 AM

PLAINVIEW, NY / ACCESSWIRE / October 6, 2022 / Vaso Corporation ("Vaso") (OTCMKTS:VASO) today announced that its application to up-list from the OTC Pink Sheets to the OTCQB market has been approved by OTC Markets Group. The effective date of the listing on OTCQB is expected to be on October 10, 2022.Compared to the OTC Pink Sheets, listing on the OTCQB market significantly increases transparency, reporting standards, management certification...

Read more

Plandai Biotechnologies, Inc. Announces Entry into Non-Binding Letter of Intent, Updates on Status of Independent Audit

October 6, 2022 6:00 AM

SAN DIEGO, CA / ACCESSWIRE / October 6, 2022 / (OTC PINK:PLPL) - Plandai Biotechnology, Inc. ("Plandai" or the "Company") announces its entry into a non-binding letter of intent with EV Hotel Corp., a Georgia corporation. EV Hotel™ developed the world's first proprietary disruptive hospitality platform - the "smart hotel," combining technology, automation, IoT, crypto and NFT with best-in-class service, stylish design, and upscale...

Read more